Citigroup Reiterates “$74.00” Price Target for Intercept Pharmaceuticals (NASDAQ:ICPT)

Intercept Pharmaceuticals (NASDAQ:ICPT) has been given a $74.00 target price by analysts at Citigroup in a research report issued on Thursday, December 21st. The brokerage currently has a “hold” rating on the biopharmaceutical company’s stock. Citigroup’s target price indicates a potential upside of 34.67% from the company’s current price.

Several other equities research analysts also recently issued reports on ICPT. BidaskClub raised Intercept Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Thursday, August 24th. Wedbush reaffirmed an “outperform” rating and set a $253.00 price target on shares of Intercept Pharmaceuticals in a research note on Friday, August 25th. ValuEngine raised Intercept Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Friday, September 1st. Wells Fargo & Co reaffirmed an “outperform” rating on shares of Intercept Pharmaceuticals in a research note on Wednesday, September 13th. Finally, Cantor Fitzgerald reaffirmed an “underweight” rating and set a $69.00 price target on shares of Intercept Pharmaceuticals in a research note on Wednesday, September 13th. Five analysts have rated the stock with a sell rating, ten have assigned a hold rating and ten have given a buy rating to the stock. The company has a consensus rating of “Hold” and a consensus price target of $140.24.

Intercept Pharmaceuticals (ICPT) opened at $54.95 on Thursday. The firm has a market capitalization of $1,379.35, a price-to-earnings ratio of -3.71 and a beta of -2.05. The company has a debt-to-equity ratio of 3.15, a current ratio of 5.95 and a quick ratio of 5.95. Intercept Pharmaceuticals has a 1 year low of $52.11 and a 1 year high of $135.59.

Intercept Pharmaceuticals (NASDAQ:ICPT) last announced its quarterly earnings data on Wednesday, November 1st. The biopharmaceutical company reported ($2.89) earnings per share (EPS) for the quarter, topping the consensus estimate of ($3.48) by $0.59. The firm had revenue of $41.33 million during the quarter, compared to the consensus estimate of $36.95 million. Intercept Pharmaceuticals had a negative return on equity of 176.51% and a negative net margin of 344.74%. The business’s revenue for the quarter was up 697.9% on a year-over-year basis. During the same period in the prior year, the business earned ($3.59) EPS. research analysts expect that Intercept Pharmaceuticals will post -13.36 earnings per share for the current fiscal year.

Several large investors have recently made changes to their positions in ICPT. FMR LLC lifted its position in shares of Intercept Pharmaceuticals by 0.7% during the 2nd quarter. FMR LLC now owns 3,750,678 shares of the biopharmaceutical company’s stock worth $454,094,000 after buying an additional 25,958 shares during the period. Carmignac Gestion lifted its position in shares of Intercept Pharmaceuticals by 0.4% during the 2nd quarter. Carmignac Gestion now owns 2,035,592 shares of the biopharmaceutical company’s stock worth $246,449,000 after buying an additional 7,400 shares during the period. Vanguard Group Inc. lifted its position in shares of Intercept Pharmaceuticals by 4.5% during the 2nd quarter. Vanguard Group Inc. now owns 1,328,133 shares of the biopharmaceutical company’s stock worth $160,797,000 after buying an additional 57,149 shares during the period. Senvest Management LLC bought a new position in shares of Intercept Pharmaceuticals during the 3rd quarter worth approximately $33,883,000. Finally, First Trust Advisors LP lifted its position in shares of Intercept Pharmaceuticals by 4.5% during the 3rd quarter. First Trust Advisors LP now owns 300,455 shares of the biopharmaceutical company’s stock worth $17,438,000 after buying an additional 13,044 shares during the period. 73.76% of the stock is currently owned by institutional investors.

TRADEMARK VIOLATION WARNING: “Citigroup Reiterates “$74.00” Price Target for Intercept Pharmaceuticals (NASDAQ:ICPT)” was first published by The Lincolnian Online and is owned by of The Lincolnian Online. If you are reading this article on another domain, it was copied illegally and reposted in violation of United States and international trademark and copyright legislation. The legal version of this article can be read at https://www.thelincolnianonline.com/2018/01/14/intercept-pharmaceuticals-icpt-given-a-74-00-price-target-at-citigroup-updated-updated.html.

Intercept Pharmaceuticals Company Profile

Intercept Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company’s product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions.

Analyst Recommendations for Intercept Pharmaceuticals (NASDAQ:ICPT)

Receive News & Ratings for Intercept Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply